There are three ways that biotechs move significantly UP or DOWN, just three
Earnings better or worse than market expects
Unforeseen positive or negative announcements between quarterly earnings
Label Expansion, welcome to the most violent!
Big Pharma is sweating as ImmunityBio (IBRX) secures exclusive U.S. rights to Japan’s Tokyo-172 BCG strain — a potential game-changer for the decade-long BCG shortage devastating bladder cancer patients. Dr. Patrick Soon-Shiong breaks it all down at AUA 2026 with major updates on supply, ANKTIVA, and the future of bladder cancer treatment.
ISRG is a 150,000,000,000 dollar business with its DaVinci systems.
IBRX could be that, with its Leonardo, then add cancer , aids, sepsis, game over
next events are Q2 guidance and sBLA stamp of approval
But we do. $GME is the new class of Berkshire
Ryan Cohen and the GME board just made another brilliant strategic move — but CNBC is still pretending they don’t understand what’s happening.
In this video we break down:
• What Ryan Cohen’s latest play actually means for GameStop
• Why Wall Street & mainstream media are still clueless - (business psychology and corporate governance)
• The real corporate strategy behind the moves
• How the meme army sees what the “experts” refuse to see
$GME + RYAN COHEN = VALUE ACCRETIVE DEALS IN THE FUTURE
• The 5 strategic reasons GME wants eBay (scale, collectibles synergies, cash deployment, Cohen’s incentives, and the pivot from physical retail)
• Ryan Cohen’s performance-based pay package — hitting $100B market cap could unlock
• How a cash + stock deal could realistically get done despite the size difference
• Synergies in gaming, TCGs, used goods, and global e-commerce infrastructure
I shall cover earnings after the earnings call, as opposed to before (like the sBLA)
The market loves lulling people to sleep then slapping them hard to wake up